Grass City 20% OFF

According to data compiled by Grand View Research, the global biotechnology market is expected to reach USD 727.1 Billion by 2025. It is also expected to grow at a CAGR of 7.4% during the forecast period. The market is expected to be driven by key factors such as regenerative medicine and the use of genetics in diagnostics. Now, technological advancements, such as artificial intelligence, are being used within the biotechnology industry to manufacture state-of-the-art equipment. Artificial intelligence and machine learning are leading the new wave of biotechnological equipment to improve and better understand diagnoses during clinical trials. PCT Ltd. (OTC:PCTL), IntelGenx Technologies Corp. (OTC:IGXT), Nemus Bioscience, Inc. (OTC:NMUS), Apotheca Biosciences, Inc. (OTC:PCFP), FSD Pharma Inc. (OTC:FSDDF)

As technology continues to advance within the biotechnology market, a need and concern for safer and cleaner equipment is required to avoid infections. According to Grand View Research, the infection control market is projected to be valued at USD 258.3 Billion by 2025. There is a growing influx of demand to develop sterilized equipment and new biologics. Companies are heavily focusing on strategies to strengthen recognition, reporting, isolation and surveillance of diseases and health concerns. “It is time to address the current obsession with the culture of blame and unrealistic hand hygiene targets by balancing out the use of other weapons we have in our infection prevention arsenal,” said Marco-Felipe King, Infection Control Postdoctoral Researcher at the Institute for Public Health and Environmental Engineering at the University of Leeds. “Appropriate antimicrobial stewardship, catheter-care, targeted cleaning, patient screening and good ventilation should go hand-in-hand with future smart technologies.”

PCT Ltd. (OTC:PCTL). After the market yesterday, the company announced that they have, “reached significant company milestones through its wholly-owned operating subsidiary Paradigm Convergence Technologies Corporation (PCT Corp.). PCT Corp. has successfully completed two Beta Site trials and installations at major healthcare facilities, which have been converted into long-term agreements for its Annihilyzer® Infection Control Systems. PCT Corp. has also established agreements with several Manufacturing Representatives for geographical territories in the healthcare market. With these milestones achieved, PCT Corp. has commenced the full-scale marketing launch of its hospital infection control systems.

PCT LTD announced today that Jody Read, current Chief Operating Officer, was promoted to Chief Executive Officer of PCT LTD and PCT Corp. Mr. Read will continue his duties as COO until it is determined that the position needs to be filled by additional personnel. Gary Grieco, PCT LTD’s current CEO, will continue as Chairman of the Board of PCT LTD and will focus his attention on setting the course for the company and overseeing the Board.

Since 2014, Gary Grieco in his prior role as PCT LTD’s CEO, has successfully built and secured funding for PCT Corp., as a startup company. He acquired and developed under his leadership its patented, proprietary technologies and directed the development of PCT Corp.’s products to the point in which PCT Corp. now has proof of concept and commercial entry in its target markets.

Read joined PCT Corp. two years ago after successfully founding and managing Customer Service Associates, Inc. (CSA) for 18 years, a $44 Million dollar a year sales and support organization for the healthcare market with over 350 employees providing equipment and services for the largest OEM’s in healthcare. He has over 33 years of medical industry background working for and with the largest manufacturers in the medical equipment business. Read’s skills in management, organization, sales, service and support will provide PCT with the leadership required to move PCT Corp. into the defined markets PCT has initially targeted.

Gary Grieco stated, ‘Jody has proven himself over the past two years to be a great team leader and his expertise in business management and healthcare equipment technologies will take PCTL and PCT Corp. to the next levels of growth and profitability. I look forward to working with Jody and the entire PCT Team to drive PCT’s growth.’

About PCT LTD: PCT LTD (“PCTL”) focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, “PCTL” aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange. The Company established entry into its target markets with commercially-viable products and now prepares to gain market share.”

IntelGenx Technologies Corp. (OTCQX:IGXT), established in 2003, is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm(TM) technology platform.

IntelGenx Corp. recently announced that its commercialization partner for RIZAPORT (10mg) in Spain, Grupo Juste, which is now part of Exeltis Healthcare, has received national marketing authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the product. RIZAPORT is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. RIZAPORT offers an innovative and potentially advantageous therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor. “This marketing authorization in Spain marks the achievement of a major milestone for our company, materially advancing RIZAPORT toward becoming the first-ever commercialized VersaFilm(TM) product to be manufactured at our new state-of-the-art facility,” said Dr. Horst G. Zerbe, President and Chief Executive Officer of IntelGenx.

Nemus Bioscience, Inc. (OTCQB:NMUS) is a biopharmaceutical company, headquartered in Long beach, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Nemus Bioscience, Inc. recently announced an agreement with Albany Molecular Research Inc. for the development and manufacture of Nemus’ proprietary cannabinoid-based active pharmaceutical ingredients (API). The agreement will capitalize on AMRI’s process chemistry expertise in the synthesis and formulation of Nemus’ proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, Nemus’ compound in development for the treatment of glaucoma. “Advancing our lead therapeutic candidates into the API manufacturing stage is a major milestone for our company and is pivotal for initiating human studies,” commented Brian Murphy, M.D., Chief Executive Officer – Chief Marketing Officer of Nemus. “Cannabinoid-based therapies have the potential to revolutionize glaucoma therapy by not only lowering intraocular pressure, but by exerting a direct neuroprotective effect on the cells of the optic nerve, thereby preserving vision.”

Apotheca Biosciences, Inc. (OTC:PCFP) is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Apotheca Biosciences recently announced the intent to purchase Nano Creaciones S.A. P.I. de D.V. Research LLC (“Nano”). Nano currently holds several patents and patents pending for the treatment of certain medical conditions, and Apotheca Biosciences is thrilled to be able to leverage their existing technology for the development of next generation CBD-based OTC formulations. Nano is on the cutting-edge of nanotechnology through their development of a cotton fiber gauze with silver nitrate nanoparticles that allow the users to discard any risk of wound infection while accelerating their tissue regeneration process. Currently, Nano is in the process of testing and fielding such medications for regulatory approval, studies, marketing, production and sales. Nano’s product has been tested in all aspects from the development and active duration of the “nanoparticles” to the “packaging” of the gauze and its density to allow its proper sterilization without damaging the product.

FSD Pharma Inc. (OTCQB:FSDDF) is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. FSD Pharma Inc. recently announced that its strategic R&D partner, SciCann Therapeutics Inc. received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy, the basis of its “Steady Stomach” product. The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive. Dr. Raza Bokhari, Chief Executive Officer of FSD Pharma stated, “This positive ISA report for CBD combination therapy is welcome news for FSD Pharma. We expect SciCann’s Steady Stomach product, currently in the phase I/II clinical development stage, to have a positive impact in the lives of IBS patients. FSD’s exclusive distribution rights for the product in Canada is in line with our company’s continuing efforts in research and development of novel and proprietary, cannabinoid-based treatments.”

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pct ltd. financial and corporate news dissemination, has been compensated five thousand dollars by paradigm convergence. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

For further



Stock Symbols